Roquette, a leading provider of pharmaceutical excipients and global leader in plant-based ingredients, is pleased to announce a strategic investment with Beren Therapeutics P.B.C., and the launch of an innovation…
The Camille and Henry Dreyfus Foundation has announced that Xiaowei Zhuang, Howard Hughes Medical Institute Investigator and David B. Arnold Jr. Professor of Science, Harvard University, is the recipient of the…
The global mRNA synthesis raw materials market size is projected to reach USD 3.3 billion by 2030. The market is expected to expand at a CAGR of 2.1% from 2023…
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA) focused on delivering innovative therapies in critical care and infectious disease, today announced that The Lancet Infectious Diseases published detailed results from…
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the promotion of Michael Sherman Blue,…
Scientist.com, der führende Marktplatz für präklinische Forschung für den biopharmazeutischen Sektor, gab heute die kürzliche Übernahme von Labs Explorer bekannt, einem bekannten französischen Netzwerk, das europäische Forschungslabore, wissenschaftliche Fachleute und…
FOXO Technologies Inc. (NYSEAM: FOXO) (“FOXO” or the “Company”), a leader in commercializing epigenetic biomarkers of health and aging, today reported financial results for the first quarter ended March 31,…
a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the first quarter ended March 31, 2023 and will host a…
a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results…
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the first quarter ended…
Today reported financial results for the first quarter ended March 31, 2023. “During the first quarter, we made significant progress on our commercial launches of RELYVRIO in the U.S. and…
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the first quarter ended March 31, 2023. The Company also posted its first quarter Letter to Stockholders and corporate presentation to…